|drug783||Clinical assessment Wiki||0.58|
There is one clinical trial.
Coronavirus Disease-19 (COVID-19) is a global pandemics which affects many organs and systems with a range of morbidities and high mortality rates. There are a number of studies revealed that COVID-19 may affect the testes and male genital tract which may in turn disrupt the gonadal functions.The current study aimed to evaluate the effect of COVID-19 on semen parameters and sex-related hormone levels.
Description: cell count percentageMeasure: Semen analyses parameters including sperm motility (total, progressive, non-progressive and immotile Time: first 1 hour
Description: cell count per milliliters of semen sample.Measure: Semen analyses parameters including sperm concentration Time: first 1 hour
Description: percentage of normal formsMeasure: Semen analyses parameters including sperm morphology Time: first 1 hour
Description: millilitersMeasure: Semen analyses parameters including semen volume Time: first 1 hour
Description: nanograms per deciliterMeasure: Sex-related hormone levels including testosterone Time: 20 minutes
Description: Units per literMeasure: Sex-related hormone levels including follicle stimulating hormone and luteinizing hormone Time: 20 minutes
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports